Sinphar Pharmaceutical Co.,Ltd. (1734.TW)
TWD 30.7
(-1.13%)
TWD 30.7
(-1.13%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 870.53 Million TWD | 28.78% |
| 2022 | 675.96 Million TWD | -28.06% |
| 2021 | 939.61 Million TWD | 2.22% |
| 2020 | 919.2 Million TWD | -16.25% |
| 2019 | 1.09 Billion TWD | 44.21% |
| 2018 | 761.01 Million TWD | 27.94% |
| 2017 | 594.81 Million TWD | 17.71% |
| 2016 | 505.32 Million TWD | -15.02% |
| 2015 | 594.65 Million TWD | 58.46% |
| 2014 | 375.28 Million TWD | -43.76% |
| 2013 | 667.34 Million TWD | -8.95% |
| 2012 | 732.91 Million TWD | 47.84% |
| 2011 | 495.75 Million TWD | -28.48% |
| 2010 | 693.14 Million TWD | 3.7% |
| 2009 | 668.41 Million TWD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 864.64 Million TWD | -5.04% |
| 2024 Q1 | 910.55 Million TWD | 4.6% |
| 2023 FY | 870.53 Million TWD | 28.78% |
| 2023 Q4 | 870.53 Million TWD | -8.48% |
| 2023 Q3 | 951.19 Million TWD | 33.15% |
| 2023 Q1 | 788.18 Million TWD | 16.6% |
| 2023 Q2 | 714.38 Million TWD | -9.36% |
| 2022 Q3 | 760.82 Million TWD | -8.58% |
| 2022 Q1 | 960.08 Million TWD | 2.18% |
| 2022 FY | 675.96 Million TWD | -28.06% |
| 2022 Q4 | 675.96 Million TWD | -11.15% |
| 2022 Q2 | 832.27 Million TWD | -13.31% |
| 2021 Q1 | 946.02 Million TWD | 2.92% |
| 2021 Q4 | 939.61 Million TWD | 0.88% |
| 2021 FY | 939.61 Million TWD | 2.22% |
| 2021 Q3 | 931.41 Million TWD | -3.21% |
| 2021 Q2 | 962.26 Million TWD | 1.72% |
| 2020 Q3 | 1.03 Billion TWD | -3.3% |
| 2020 FY | 919.2 Million TWD | -16.25% |
| 2020 Q4 | 919.2 Million TWD | -10.91% |
| 2020 Q1 | 1.15 Billion TWD | 5.11% |
| 2020 Q2 | 1.06 Billion TWD | -7.51% |
| 2019 Q2 | 901.49 Million TWD | 5.75% |
| 2019 FY | 1.09 Billion TWD | 44.21% |
| 2019 Q4 | 1.09 Billion TWD | 12.38% |
| 2019 Q3 | 976.58 Million TWD | 8.33% |
| 2019 Q1 | 852.48 Million TWD | 12.02% |
| 2018 Q4 | 761.01 Million TWD | 3.07% |
| 2018 Q1 | 678.96 Million TWD | 14.15% |
| 2018 Q2 | 688.04 Million TWD | 1.34% |
| 2018 FY | 761.01 Million TWD | 27.94% |
| 2018 Q3 | 738.34 Million TWD | 7.31% |
| 2017 Q4 | 594.81 Million TWD | -0.79% |
| 2017 FY | 594.81 Million TWD | 17.71% |
| 2017 Q2 | 593.12 Million TWD | 0.95% |
| 2017 Q3 | 599.57 Million TWD | 1.09% |
| 2017 Q1 | 587.52 Million TWD | 16.27% |
| 2016 Q1 | 684.13 Million TWD | 15.05% |
| 2016 Q4 | 505.32 Million TWD | -24.93% |
| 2016 Q2 | 746.31 Million TWD | 9.09% |
| 2016 Q3 | 673.15 Million TWD | -9.8% |
| 2016 FY | 505.32 Million TWD | -15.02% |
| 2015 Q4 | 594.65 Million TWD | -11.94% |
| 2015 Q3 | 675.3 Million TWD | 56.94% |
| 2015 Q1 | 414.4 Million TWD | 10.43% |
| 2015 Q2 | 430.28 Million TWD | 3.83% |
| 2015 FY | 594.65 Million TWD | 58.46% |
| 2014 Q2 | 677.97 Million TWD | -12.97% |
| 2014 Q3 | 944.29 Million TWD | 39.28% |
| 2014 FY | 375.28 Million TWD | -43.76% |
| 2014 Q4 | 375.28 Million TWD | -60.26% |
| 2014 Q1 | 778.98 Million TWD | 16.73% |
| 2013 Q4 | 667.34 Million TWD | -1.15% |
| 2013 FY | 667.34 Million TWD | -8.95% |
| 2013 Q2 | 832.86 Million TWD | 78.29% |
| 2013 Q1 | 467.13 Million TWD | -36.26% |
| 2013 Q3 | 675.08 Million TWD | -18.94% |
| 2012 Q2 | 644.96 Million TWD | 0.1% |
| 2012 FY | 732.91 Million TWD | 47.84% |
| 2012 Q1 | 644.3 Million TWD | 29.96% |
| 2012 Q3 | 649.34 Million TWD | 0.68% |
| 2012 Q4 | 732.91 Million TWD | 12.87% |
| 2011 Q4 | 495.75 Million TWD | -28.91% |
| 2011 Q1 | 729.92 Million TWD | 5.31% |
| 2011 Q2 | 698.24 Million TWD | -4.34% |
| 2011 FY | 495.75 Million TWD | -28.48% |
| 2011 Q3 | 697.33 Million TWD | -0.13% |
| 2010 Q4 | 693.14 Million TWD | 0.0% |
| 2010 FY | 693.14 Million TWD | 3.7% |
| 2009 FY | 668.41 Million TWD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Apex Biotechnology Corp. | -201.21 Million TWD | 532.637% |
| Panion & Bf Biotech Inc. | 193.2 Million TWD | -350.567% |
| Chunghwa Chemical Synthesis & Biotech Co., Ltd. | 939.54 Million TWD | 7.345% |
| GenMont Biotech Incorporation | 2.71 Million TWD | -31999.226% |
| Abnova (Taiwan) Corporation | -415.8 Million TWD | 309.358% |
| Adimmune Corporation | 685.12 Million TWD | -27.061% |
| Tanvex BioPharma, Inc. | 1.35 Billion TWD | 35.565% |
| Polaris Group | -2.41 Billion TWD | 135.988% |
| Energenesis Biomedical CO.,LTD. | -246.6 Million TWD | 453.002% |
| UnicoCell Biomed Co., Ltd. | 54.43 Million TWD | -1499.359% |
| PELL Bio-Med Technology Co. Ltd. | 4.88 Million TWD | -17735.095% |